10.25 USD
↗ 0.19 (1.89%)AT CLOSE (11:59 AM EDT)
Immix Biopharma, Inc. Common Stock
IMMXNASDAQ • USD
10.25
↗ 0.00 (0.00%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
10.25
↗ 0.00 (0.00%)
Market: CLOSED
IMMX is currently priced at $10.25. The stock presents a mixed profile: our models indicate a Buy for technical indicators, while underlying fundamentals flash a Sell. Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Jul 17, 2026.
Open?$9.80
High?$10.58
Low?$9.69
Prev. Close?$10.06
Volume?1.1M
Avg. Volume?2.0M
VWAP?$10.21
Rel. Volume?0.53x
Bid / Ask
Bid?$10.13 × 100
Ask?$10.50 × 2.7K
Spread?$0.37
Midpoint?$10.32
Valuation & Ratios
Market Cap?729.7M
Shares Out?54.4M
Float?36.2M
Float %?66.6%
P/E Ratio?N/A
P/B Ratio?8.65
EPS?-$0.49
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
Themes
Employees
21
Market Cap
716.2M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2021-12-16
Address
11400 WEST OLYMPIC BLVD.
LOS ANGELES, CA 90064
Phone: (888) 958-1084
LOS ANGELES, CA 90064
Phone: (888) 958-1084
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?100
Momentum?23
Short Sent.?28
Piotroski F-Score?0/9Weak
Altman Z-Score?36.34Safe
Confidence?45%Low
Short InterestSqueeze Risk
Short % of Float?21.75%Squeeze Risk
Short Interest?7.9M
Days to Cover?2.7
Free Float36.2M
Avg Daily Volume2.9M
Settlement Date2026-06-30
Financial Health
Current Ratio?8.76Strong
Quick Ratio?8.76Strong
Cash Ratio?7.52Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?N/A▾
P/B?8.65HIGH▾
Peers100
S&P22
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-18.2CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-41.4%WEAK▾
S&P3
ROA?-36.5%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-32770055
Enterprise Value?$650.4M
Fundamentals ratios updated end of day